

UNAUDITED FINANCIAL RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2010

AVENTIS PHARMA LIMITED

Registered Office : Aventis House, 54/A, Sir Mathuradas Vasanji Road,
Andheri East, Mumbai 400 093

(Rs. Million)

Particulars	Quarter ended 30.06.2010 (Unaudited)	Quarter ended 30.06.2009 (Unaudited)	Half year ended 30.06.2010 (Unaudited)	Half year ended 30.06.2009 (Unaudited)	Year ended 31.12.2009 (Audited)
1 (a) Net Sales	2,715	2,499	5,229	4,788	9,744
(b) Other Operating income	190	169	359	395	781
Total	2,905	2,668	5,588	5,183	10,525
2 Expenditure					
(a) (Increase)/ Decrease in stock in trade and work in progress	160	(68)	170	(209)	(623)
(b) Consumption of raw materials	808	968	1,645	1,915	3,525
(c) Purchase of traded goods	400	297	814	601	1,918
(d) Employees cost	408	352	784	678	1,440
(e) Depreciation	47	43	90	85	173
(f) Other	504	421	1,017	884	2,006

Particulars	Quarter ended 30.06.2010 (Unaudited)	Quarter ended 30.06.2009 (Unaudited)	Half year ended 30.06.2010 (Unaudited)	Half year ended 30.06.2009 (Unaudited)	Year ended 31.12.2009 (Audited)
expenditure					
(g) Total	2,327	2,013	4,520	3,954	8,439
3 Profit from Other income Interest(1-2)	578	655	1,068	1,229	2,086
4 Other Income	63	80	120	174	330
5 Profit before Interest (3+4)	641	735	1,188	1,403	2,416
6 Interest	-	-	-	-	1
7 Profit before tax(5-6)	641	735	1,188	1,403	2,415
8 Tax expense	217	264	403	527	841
9 Net Profit for the period(7-8)	424	471	785	876	1,574
10 Paid-up equity share capital(Face Value of Rs. 10 per share)	230	230	230	230	230
11 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	8,916
12 Earnings Per Share (EPS) (Rs.) Basic and	18.43	20.48	34.13	38.09	68.35

Particulars	Quarter ended 30.06.2010 (Unaudited)	Quarter ended 30.06.2009 (Unaudited)	Half year ended 30.06.2010 (Unaudited)	Half year ended 30.06.2009 (Unaudited)	Year ended 31.12.2009 (Audited)
diluted EPS for the period, for the year to date and for the previous year					
13 Public Shareholding					
- Number of Shares	9,121,035	9,120,955	9,121,035	9,120,955	9,120,955
- Percentage of Shareholding	39.60%	39.60%	39.60%	39.60%	39.60%
14 Promoters and Promoter group Shareholding					
a) Pledged/Encumbered					
- Number of Shares	NIL	2,365,920	NIL	2,365,920	2,365,920
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	NIL	17.01%	NIL	17.01%	17.01%
- Percentage of shares (as a % of total share capital of the company)	NIL	10.27%	NIL	10.27%	10.27%
b) Non-encumbered					

Particulars	Quarter ended 30.06.2010 (Unaudited)	Quarter ended 30.06.2009 (Unaudited)	Half year ended 30.06.2010 (Unaudited)	Half year ended 30.06.2009 (Unaudited)	Year ended 31.12.2009 (Audited)
- Number of Shares	13,909,587	11,543,747	13,909,587	11,543,747	11,543,747
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	100.00%	82.99%	100.00%	82.99%	82.99%
- Percentage of shares (as a % of total share capital of the company)	60.40%	50.13%	60.40%	50.13%	50.13%

Notes:

- The above results were approved by the Board of Directors of the Company at its Meeting held on July 19, 2010.
- In accordance with Clause 41 of the Listing Agreement with the Stock Exchanges, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the half year ended June 30, 2010.
- The Board of Directors has declared an Interim Dividend of Rs.4 per Equity share of Rs 10 to be paid to those Members whose names appear on the Register of Members of the Company on July 27, 2010 being the Record Date.
- The Statement of Assets and Liabilities as required under clause 41(V)(h) of the Listing Agreement is as under:

Rs Million

Particulars	As at June 30, 2010 (Unaudited)	As at June 30, 2009 (Unaudited)	As at December 31, 2009 (Unaudited)
Shareholder's funds:			
a) Share capital:	230	230	230

Particulars	As at June 30, 2010 (Unaudited)	As at June 30, 2009 (Unaudited)	As at December 31, 2009 (Unaudited)
b) Reserves and Surplus*	9,762	8,838	9,088
TOTAL	9,992	9,068	9,318
Fixed Assets (including capital work in progress)	1,765	1,535	1,720
Investments	53	52	52
Deferred tax assets (Net)	157	149	146
Current assets loans and advances			
a) Inventories	2,320	2,137	2,311
b) Sundry debtors	626	666	527
c) Cash and Bank balances	5,799	5,467	5,861
d) Loans and advances	1,541	1,286	1,437
Less: Current Liabilities and Provisions			
a) Liabilities	1,447	1,472	1,582
Provisions*	822	752	1,154
TOTAL	9,992	9,068	9,318

*After considering Interim Dividend.

- The break up of Net Sales is as follows:

Rs Million

	Quarter ended June 30, 2010	Quarter ended June 30, 2009	Growth %	Half Year ended June 30, 2010	Half Year ended June 30, 2009	Growth %

	Quarter ended June 30, 2010	Quarter ended June 30, 2009	Growth %	Half Year ended June 30, 2010	Half Year ended June 30, 2009	Growth %
Domestic Sales- Others	2,177	1,888	15.3%	4,150	3,509	18.3%
Domestic Sales- Rabipur	-	-	-	-	92	-100.0%
Export Sales	538	611	-12.0%	1,079	1,187	-9.1%
Total sales	2,715	2,499	8.6%	5,229	4,788	9.2%

Excluding the impact of discontinuation of Rabipur distribution, comparable sales growth for the six months ended June 30, 2010 is 11.4%.

- Throughout 2010, the Company will incur planned expenditure in two critical projects-slated to be growth drivers :
 - "Prayas"- a project to deliver high quality low cost healthcare to the rural population ; and
 - Entering the Over The Counter (OTC) market.
- The Company has a single business segment namely 'Pharmaceutical Business'.
- Information on investor complaints is furnished below:

Pending as on April 1, 2010	Received during the quarter	Disposed of during the quarter	Pending as on June 30, 2010
Nil	6	6	Nil

- The figures for the previous periods have been re-grouped, wherever necessary.

AVENTIS PHARMA LIMITED
DR. SHAILESH AYYANGAR

MANAGING DIRECTOR